Primaquine double dose for 7 days is inferior to single-dose treatment for 14 days in preventing Plasmodium vivax recurrent episodes in Suriname

References

• Gething PW, Elyazar IRF, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6(9):e1814.
   PubMed Web of Science ®Google Scholar
• Regional Profiles. World Malaria Report. World Health Organization. Available from: http://www.who.int/malaria/publications/world-malaria-report-2015/wmr2015-profiles.pdf. Accessed June 4, 2016.
   Google Scholar
• WHO Library Cataloguing-in-Publication Data. Control and Elimination of Plasmodium vivax Malaria: A Technical Brief. Available from: http://www.who.int/malaria/publications/world-malaria-report-2015/wmr2015 /. Accessed June 4, 2016.
   Google Scholar
• Cogswell FB. The hypnozoite and relapse in primate malaria. Clin Microbiol Rev. 1992:5(1):26–35.
   PubMed Web of Science ®Google Scholar
• Baird KJ, Maguire JD, Price RN. Diagnosis and treatment of Plasmodium vivax malaria.. Adv Parasitol. 2012;80:203–70.
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the treatment of malaria. 3rd edition. Geneva: World Health Organization; 2015. Available from: http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1. Accessed December 29, 2015.
   Google Scholar
• Alvarez G, Pineros J, Tobon A, et al. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am J Trop Med Hyg. 2006;75(4):605–609.
   PubMed Web of Science ®Google Scholar
• Murphy GS, Basri H, Purnomo MS, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1993;341(8837):91–100.
   PubMed Web of Science ®Google Scholar
• Than M, Kyaw MP, Soe AY, Gyi KK, Sabai M, Oo M. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg. 1995;89(3):307–308.
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Gutierrez P, et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg. 2001;65(2):90–93.
   PubMed Web of Science ®Google Scholar
• Bunnag D, Karbwang J, Thanavibul A, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg. 1994;88:218–219.
   PubMed Web of Science ®Google Scholar
• Wilairatana P, Silachamroon S, Krudsoord S, et al. Efficacy of primaquine regimens for primaquine-resistant plasmodium vivax malaria in Thailand. Am J Trop Med Hyg. 1999;61(6):973–977.
   PubMed Web of Science ®Google Scholar
• Baird JK, Rieckmann, KH. Can primaquine therapy for vivax malaria be improved. Trends Parasitol. 2003;19(3):115–120.
   PubMed Web of Science ®Google Scholar
• Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195: 927–933.
   PubMed Web of Science ®Google Scholar
• Goller JL, Jolley D, Ringwald P, Biggs B. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg. 2007;76(2):203–207.
   PubMed Web of Science ®Google Scholar
• Bunnag D, Karbwang J, Thanavibul A, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg. 1994;88:218–219.
   PubMed Web of Science ®Google Scholar
• Krudsoord S, Tangpukdee N, Wilairatana P, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg. 2008;78(5):736–740.
   PubMed Web of Science ®Google Scholar
• Dao NVH, Cuong BT, Ngoa ND. Vivax malaria preliminary observations following a shorter course of treatment with artesunate plus primaquine. Trans R Soc Trop Med Hyg. 2007;101:534–539.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Treatment of Malaria (Guidelines For Clinicans). Available from: http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf Accessed June 4, 2016.
   Google Scholar
• Clyde DF, McCarthy VC. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg. 1977;26:(3):562–563.
   PubMed Web of Science ®Google Scholar
• Ferreira M, Castro MC. Challenges for malaria elimination in Brazil. Malar J. 2016; 15:284.
   PubMed Web of Science ®Google Scholar
• John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11: 280. Available from: http://doi.org/10.1186/1475-2875-11-280. Accessed December 29, 2015.
   Google Scholar
• Duarte EC, Pang LW, Ribeiro LC, Fontes CJF. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg. 2001;65(5):471–476.
   PubMed Web of Science ®Google Scholar
• Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Guia prático de tratamento da malária no Brasil. Brasília: Ministério da Saúde, 2010:36. [Portugese]
   Google Scholar
• Imwong M, Pukrittayakamee S, Grüner AC, et al. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J; 2005;4(1):20.
   PubMedGoogle Scholar
• The GPHF-Minilab®. Protection against counterfeited and substandard pharmaceuticals. Available from: www.gphf.org/web/en/minilab. Accessed June 4, 2016.
   Google Scholar
• Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg. 1997;56:621–626.
   PubMed Web of Science ®Google Scholar
• Foley M, Ranford-Cartwright LC, Babiker HA. Rapid and simple method for isolating malaria DNA from fingerprick samples of blood. Mol Biochem Parasitol. 1992;53(1–2):241–244.
   PubMed Web of Science ®Google Scholar
• Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP. Polymorphism at the merozoite surface protein-3alpha locus of Plasmodium vivax: global and local diversity. Am J Trop Med Hyg. 1999:6(4):518–525.
   Google Scholar
• Schmidt LH, Fradkin R, Vaughan D, Rasco J. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg. 1977;26:1116–1128.
   PubMed Web of Science ®Google Scholar
• Durand S, Cabezas C, Lescano AG, et al. Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru. Am J Trop Med Hyg. 2014;91(1):18–26.
   PubMed Web of Science ®Google Scholar
• Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull WHO. 1960;22:621–631.
   PubMedGoogle Scholar
• Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One. 2008;3(8): e2861.
   PubMed Web of Science ®Google Scholar
• Rajgor DD, Gogtay NJ, Kadam VS, et al. Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India. Trans R Soc Trop Med Hyg. 2003;97(4):438–40.
   PubMed Web of Science ®Google Scholar
• Galappaththy GN, Tharyan P, Kirubakaran R. Cochrane Database Syst Rev. 2013;(10):CD004389.
   Google Scholar
• Hiwat H, Hardjopawiro L, Takken W, Villegas L. Novel strategies lead to pre-elimination in previously high-risk areas in Suriname, South America. Malar J. 2012;11(1):10.
   PubMedGoogle Scholar